[go: up one dir, main page]

WO2012019192A3 - Cell-permeable molecules as growth factor receptor antagonists - Google Patents

Cell-permeable molecules as growth factor receptor antagonists Download PDF

Info

Publication number
WO2012019192A3
WO2012019192A3 PCT/US2011/046956 US2011046956W WO2012019192A3 WO 2012019192 A3 WO2012019192 A3 WO 2012019192A3 US 2011046956 W US2011046956 W US 2011046956W WO 2012019192 A3 WO2012019192 A3 WO 2012019192A3
Authority
WO
WIPO (PCT)
Prior art keywords
growth factor
factor receptor
cell
molecules
receptor antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2011/046956
Other languages
French (fr)
Other versions
WO2012019192A2 (en
Inventor
Ravi Iyengar
Aislyn Dara Wist Boran
Yibang Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Icahn School of Medicine at Mount Sinai
Original Assignee
Mount Sinai School of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mount Sinai School of Medicine filed Critical Mount Sinai School of Medicine
Publication of WO2012019192A2 publication Critical patent/WO2012019192A2/en
Publication of WO2012019192A3 publication Critical patent/WO2012019192A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/485—Epidermal growth factor [EGF] (urogastrone)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention provides growth factor receptor inhibitory molecules and methods of identifying such molecules, as well as methods of making such molecules and methods of using such molecules, for example in the treatment of cancer such as breast, colorectal, pancreatic, or lung cancer.
PCT/US2011/046956 2010-08-06 2011-08-08 Cell-permeable molecules as growth factor receptor antagonists Ceased WO2012019192A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US37158910P 2010-08-06 2010-08-06
US61/371,589 2010-08-06
US201161454209P 2011-03-18 2011-03-18
US61/454,209 2011-03-18

Publications (2)

Publication Number Publication Date
WO2012019192A2 WO2012019192A2 (en) 2012-02-09
WO2012019192A3 true WO2012019192A3 (en) 2012-05-03

Family

ID=45560114

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/046956 Ceased WO2012019192A2 (en) 2010-08-06 2011-08-08 Cell-permeable molecules as growth factor receptor antagonists

Country Status (1)

Country Link
WO (1) WO2012019192A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013163423A1 (en) 2012-04-25 2013-10-31 Musc Foundation For Research Development Compositions and methods for wound healing and tissue repair
JP2022551467A (en) * 2019-10-10 2022-12-09 ザ リサーチ ファウンデイション フォー ザ ステイト ユニバーシティー オブ ニューヨーク Analgesic and narcotic peptides and other drugs
WO2024105656A1 (en) * 2022-11-18 2024-05-23 Ramot At Tel-Aviv University Ltd. Her receptor derived peptides and methods of use thereof

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
A. BARDELLI ET AL: "Uncoupling signal transducers from oncogenic MET mutants abrogates cell transformation and inhibits invasive growth", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 95, no. 24, 24 November 1998 (1998-11-24), pages 14379 - 14383, XP055012290, ISSN: 0027-8424, DOI: 10.1073/pnas.95.24.14379 *
ANONYMOUS: "EGFR (Epidermal Growth Factor Receptor) inhibitor: Petide Antagonists targeting Juxtamembrane.", 23 July 2009 (2009-07-23), XP002663757, Retrieved from the Internet <URL:http://mssm.technologypublisher.com/technology/3228> [retrieved on 20111116] *
CHRISTENSEN J G ET AL: "c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention", CANCER LETTERS, vol. 225, no. 1, 8 July 2005 (2005-07-08), NEW YORK, NY, US, pages 1 - 26, XP027608071, ISSN: 0304-3835, [retrieved on 20050708] *
HOOSHMAND RAD ET AL: "PDGF alpha-receptor mediated cellular responses are not dependent on Src family kinases in endothelial cells.", JOURNAL OF CELL SCIENCE, vol. 111, no. 5, 1 March 1998 (1998-03-01), pages 607 - 614, XP055012379, ISSN: 0021-9533 *
JAE-HO LEE ET AL: "A novel germ line juxtamembrane Met mutation in human gastric cancer", ONCOGENE, vol. 19, no. 43, 1 January 2000 (2000-01-01), pages 4947 - 4953, XP055012366, ISSN: 0950-9232, DOI: 10.1038/sj.onc.1203874 *
P. M. CHAN ET AL: "Autoinhibition of the Kit Receptor Tyrosine Kinase by the Cytosolic Juxtamembrane Region", MOLECULAR AND CELLULAR BIOLOGY, vol. 23, no. 9, 1 May 2003 (2003-05-01), pages 3067 - 3078, XP055012332, ISSN: 0270-7306, DOI: 10.1128/MCB.23.9.3067-3078.2003 *

Also Published As

Publication number Publication date
WO2012019192A2 (en) 2012-02-09

Similar Documents

Publication Publication Date Title
AU2016204376A1 (en) MicroRNA-based methods and compositions for the diagnosis and treatment of ovarian cancer
PH12013502230A1 (en) Multispecific antibodies
HK1199100A1 (en) Methods and compositions for the treatment and diagnosis of colorectal cancer
WO2010003520A3 (en) Anti-tumor immunotherapy
WO2012058592A3 (en) Non-antagonistic egfr-binding molecules and immunoconjugates thereof
WO2011047087A3 (en) Protein detection via nanoreporters
MX2010004374A (en) Protein scaffolds.
MX345909B (en) Anti-fgfr3 antibodies and methods using same.
MX336001B (en) Anti-axl antibodies and methods of use.
WO2010099161A8 (en) Micrornas in never-smokers and related materials and methods
WO2009108860A8 (en) Microrna-based methods and compositions for the diagnosis, pronosis and treatment of prostate related disorders
EA024630B9 (en) Pyrazole derivatives as calcium release-activated calcium (crac) channel inhibitors
PH12013500207A1 (en) Dual variable domain immunoglobulins and uses thereof
PH12013500337A1 (en) Dual variable domain immunoglobulins and uses thereof
MX2013004979A (en) Dual variable domain immunoglobulins and uses thereof.
MX2009008347A (en) Oxabicycloheptanes and oxabicycloheptenes, their preparation and use.
WO2014018563A3 (en) Methods for the treatment of cancer
WO2012058588A3 (en) Novel egfr-binding molecules and immunoconjugates thereof
EP4276200A3 (en) Fgfr-tacc fusion proteins and methods thereof
WO2009111643A3 (en) Microrna markers for recurrence of colorectal cancer
WO2011141823A3 (en) Methods of treating and/or preventing cell proliferation disorders with il-17 antagonists
WO2010104598A3 (en) Kinase protein binding inhibitors
HK1202313A1 (en) Methods and compositions for the treatment and diagnosis of bladder cancer
HK1199290A1 (en) Methods and compositions for the treatment and diagnosis of breast cancer
MX2013001473A (en) Antibodies against il-18r1 and uses thereof.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11750002

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11750002

Country of ref document: EP

Kind code of ref document: A2